Medlogics Device’s Cobra Coronary Stent System has received the CE Mark based on the chronic preclinical implants performed at Saint Joseph’s Translational Research Institute (SJTRI) in Atlanta, which demonstrated the safety and efficacy of the stent.
The Cobra Coronary Stent System combines a unique design and a cobalt super alloy for thinner struts without sacrificing radial strength, according to the Santa Rosa, Calif.-based company.
In addition to working on its BMS program, SJTRI is conducting further research with Medlogics on their drug-eluting stent (DES) programs.
Medlogics said its DES has a silica-based coating that is gradually absorbed by the body after delivery of the drug, potentially reducing the risk of clotting and the burden of pharmacotherapy.
Medlogics recently reported that it has licensed CV Therapeutics’ proprietary biopolymer stent coating technology for the development of a new stent based on the Cobra platform.